BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu X, Cai S, Li Z, Zheng C, Xue X, Zeng J, Peng J. Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis. Virol J 2016;13:64. [PMID: 27062520 DOI: 10.1186/s12985-016-0522-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence 2017;11:85-93. [PMID: 28138226 DOI: 10.2147/PPA.S127139] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
2 Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z. Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma. Infect Agent Cancer. 2017;12:47. [PMID: 28852419 DOI: 10.1186/s13027-017-0153-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
3 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang X, Liu Y, Sun J, Gong W, Sun P, Kong X, Yang M, Zhang W. Mitofusin-2 acts as biomarker for predicting poor prognosis in hepatitis B virus related hepatocellular carcinoma. Infect Agent Cancer 2018;13:36. [PMID: 30498519 DOI: 10.1186/s13027-018-0212-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Wang ML, Chen EQ, Zhang DM, Du LY, Yan LB, Zhou TY, Lei XZ, Lei BJ, Lu JJ, Liao J, Tang H. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. J Viral Hepat 2017;24 Suppl 1:21-8. [PMID: 29082645 DOI: 10.1111/jvh.12792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
7 Chen P, Yang N, Xu L, Zhao F, Zhang M. Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma. Infect Agent Cancer 2019;14:39. [PMID: 31768188 DOI: 10.1186/s13027-019-0256-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Liu H, Yang L. Dynamic change of depression and anxiety after chemotherapy among patients with ovarian cancer. Medicine (Baltimore) 2019;98:e16620. [PMID: 31374028 DOI: 10.1097/MD.0000000000016620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
9 Yang YM, Choi EJ. Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection. Ther Clin Risk Manag. 2017;13:1273-1285. [PMID: 29033575 DOI: 10.2147/tcrm.s143286] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
10 Tang X, Huang W, Kang J, Ding K. Early dynamic changes of quasispecies in the reverse transcriptase region of hepatitis B virus in telbivudine treatment. Antiviral Res 2021;195:105178. [PMID: 34509461 DOI: 10.1016/j.antiviral.2021.105178] [Reference Citation Analysis]
11 Li H, Wang X, Tang J, Zhao H, Duan M. Decreased expression levels of ELOVL6 indicate poor prognosis in hepatocellular carcinoma. Oncol Lett 2019;18:6214-20. [PMID: 31788097 DOI: 10.3892/ol.2019.10974] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kader C, Sunbul M, Das YK, Yarim M, Bedir A, Karaca E, Celikbilek M, Ozaras R. Telbivudine attenuates gentamicin-induced kidney injury in rats. Int J Antimicrob Agents 2017;49:595-602. [PMID: 28373116 DOI: 10.1016/j.ijantimicag.2017.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Lu JB, Cai SH, Pan YH, Yun JP. Altered epidermal fatty acid-binding protein expression in hepatocellular carcinoma predicts unfavorable outcomes. Cancer Manag Res 2018;10:6275-84. [PMID: 30538573 DOI: 10.2147/CMAR.S181555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
14 Sun J, Li Y, Sun X, Yu H, Liu Y. Dynamic Changes of the Aspartate Aminotransferase-to-Platelet Ratio and Transient Elastography in Predicting a Histologic Response in Patients With Chronic Hepatitis B After Entecavir Treatment. J Ultrasound Med 2019;38:1441-8. [PMID: 30244494 DOI: 10.1002/jum.14822] [Reference Citation Analysis]
15 Guo X, Wu J, Wei F, Ouyang Y, Li Q, Liu K, Wang Y, Zhang Y, Chen D. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. Int J Antimicrob Agents 2018;52:201-9. [PMID: 29654894 DOI: 10.1016/j.ijantimicag.2018.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
16 Yan Z, Qiao B, Zhang H, Wang Y, Gou W. Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study. Medicine (Baltimore) 2018;97:e11716. [PMID: 30075577 DOI: 10.1097/MD.0000000000011716] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Cai S, Cao J, Yu T, Xia M, Peng J. Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine. Medicine (Baltimore) 2017;96:e7021. [PMID: 28562554 DOI: 10.1097/MD.0000000000007021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
18 Yang YW, Tsai MK, Yang CY, Lee CY, Chiang BL, Lai HS. Telbivudine for renal transplant recipients with chronic hepatitis B infection: a randomized controlled trial with early termination. Clin Exp Nephrol 2020;24:474-82. [PMID: 32219622 DOI: 10.1007/s10157-020-01850-7] [Reference Citation Analysis]
19 Cai S, Li Z, Yu T, Xia M, Peng J. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs. Infect Drug Resist 2018;11:469-77. [PMID: 29662321 DOI: 10.2147/IDR.S163038] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
20 Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Reference Citation Analysis]
21 Chen Q, Cao C, Gong L, Zhang Y. Health related quality of life in stroke patients and risk factors associated with patients for return to work. Medicine (Baltimore) 2019;98:e15130. [PMID: 31008934 DOI: 10.1097/MD.0000000000015130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
22 Liu B, Shen B, Mei M, Li L, Wang X, Zhao H. Potential Effects of Telbivudine Versus Entecavir on Renal Function in Patients With Chronic Hepatitis B Virus Receiving Glucocorticoids Therapy. Ther Apher Dial 2020;24:56-63. [PMID: 31090170 DOI: 10.1111/1744-9987.12839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Zheng H, Liu H, Hao A, Zhang M, Wang D. Association between serum Cystatin C and renal injury in patients with chronic hepatitis B. Medicine (Baltimore) 2020;99:e21551. [PMID: 32769895 DOI: 10.1097/MD.0000000000021551] [Reference Citation Analysis]
24 Zeng J, Zheng C, Li H. Effectiveness of tenofovir or telbivudine in preventing HBV vertical transmission for pregnancy. Medicine (Baltimore) 2019;98:e15092. [PMID: 30946367 DOI: 10.1097/MD.0000000000015092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
25 Zhong C, Yin J, Zheng Z, Cai S, Gao Y. Risk factors associated with fatigue in chronic hepatitis B patients. Patient Prefer Adherence 2019;13:1065-72. [PMID: 31456634 DOI: 10.2147/PPA.S206953] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Ren S, Chang Y, Zhang Q, Wang X, Niu H, Chen L, Lv C, Zhang Z, Xiang X, Zhu L, Li H. How to estimate renal function in patients with liver disease: choosing the most suitable equation. Int Urol Nephrol 2019;51:677-90. [PMID: 30830657 DOI: 10.1007/s11255-019-02110-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yen CH, Lai CC, Shia TH, Chen M, Yu HC, Liu YP, Chang FR. Gynura divaricata attenuates tumor growth and tumor relapse after cisplatin therapy in HCC xenograft model through suppression of cancer stem cell growth and Wnt/β-catenin signalling. J Ethnopharmacol 2018;213:366-75. [PMID: 28729225 DOI: 10.1016/j.jep.2017.07.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Wang L, Chen P, Zheng C. Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B. Infect Drug Resist 2018;11:2179-85. [PMID: 30519055 DOI: 10.2147/IDR.S186719] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr 2019;8:361-9. [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
30 Sun J, Li Y, Sun X, Liu Y, Zheng D, Fan L. Association between abdominal obesity and liver steatosis and fibrosis among patients with chronic hepatitis B measured by Fibroscan. Exp Ther Med 2019;18:1891-8. [PMID: 31410151 DOI: 10.3892/etm.2019.7727] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Huang M, Zhong J, Lu C, Deng F, Li L, Nong Y, Liang L, Qin H, Deng Y. Genotypic Resistance Remains A Concern In Chronic Hepatitis B Patients With High Viral Load After Lamivudine And Adefovir Combination Therapy. Pharmgenomics Pers Med 2019;12:297-303. [PMID: 31695474 DOI: 10.2147/PGPM.S224256] [Reference Citation Analysis]
32 Zheng C, Yan H, Zeng J, Cai S, Wu X. Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B. Infect Drug Resist. 2019;12:845-854. [PMID: 31114265 DOI: 10.2147/idr.s195144] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
33 Guo YF, Pan JX, Zhuang WH. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome. Infect Agent Cancer 2018;13:40. [PMID: 30559832 DOI: 10.1186/s13027-018-0215-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Liu Y, Wang X, Xiao J, Sun J, Zhang Y. Prognostic value of postoperative change in liver stiffness in patients with HBV-related hepatocellular carcinoma. J Int Med Res 2020;48:300060520908763. [PMID: 32290747 DOI: 10.1177/0300060520908763] [Reference Citation Analysis]
35 Zheng Z, Liao W, Liu L, Cai S, Zhu H, Yin S. Effect of nucleos(t)ide analogue on serum HBsAg level in chronic hepatitis B patients: A 3-years study. Biomed Pharmacother 2020;122:109698. [PMID: 31918272 DOI: 10.1016/j.biopha.2019.109698] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]